July 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Jul 27, 2026, 16:33

Martyna Lewand: Major Immunology Deal Brings FB102 to argenx

Martyna Lewand, Editor-in-Chief at BioBriefs.com, shared a post on LinkedIn։

”From today’s BioBriefs.com – You should subscribe, it’s free:

Immunology M and A accelerates pipeline

argenx agreed to buy Forte Biosciences for $2.2 billion in cash, valuing Forte at 77 dollar per share and marking a continuation of deal momentum across mid-cap immunology. The acquisition is designed to bring Forte’s phase 2-stage anti-CD122 antibody FB102 into argenx’s antibody pipeline, following earlier clinical validation in vitiligo.

Forte’s FB102 showed a 29.6% improvement in facial vitiligo in a recent phase 1b study, and argenx expects later this year readouts in celiac disease. The companies position FB102 as a potential ‘pipeline-in-a-product’ opportunity that could expand into other autoimmune diseases.

The buyout also ends Forte’s independent development after pressure from shareholders in 2022, when Forte’s atopic dermatitis program failed in phase 2 and the company faced calls to liquidate. argenx’s commercial and late-stage development capabilities are intended to extend FB102’s clinical path.

Key takeaway: argenx’s acquisition targets a mechanism aimed at T-cell and NK-cell activity, aiming to broaden antibody competition in autoimmune care with an asset now moving through late early-stage development.”

Stay updated with Hemostasis Today.